Feasibility of Proton Beam Therapy as a Rescue Therapy in Heavily Pre-Treated Retinoblastoma Eyes.

EBRT eye preserving therapy in-field malignancies subsequent primary malignancies

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
13 Apr 2021
Historique:
received: 28 02 2021
revised: 09 04 2021
accepted: 11 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 1 5 2021
Statut: epublish

Résumé

Despite the increased risk of subsequent primary tumors (SPTs) external beam radiation (EBRT) may be the only therapeutic option to preserve a retinoblastoma eye. Due to their physical properties, proton beam therapy (PBT) offers the possibility to use the effectiveness of EBRT in tumor treatment and to decisively reduce the treatment-related morbidity. We report our experiences of PBT as rescue therapy in a retrospectively studied cohort of 15 advanced retinoblastoma eyes as final option for eye-preserving therapy. The average age at the initiation of PBT was 35 (14-97) months, mean follow-up was 22 (2-46) months. Prior to PBT, all eyes were treated with systemic chemotherapy and a mean number of 7.1 additional treatments. Indication for PBT was non-feasibility of intra-arterial chemotherapy (IAC) in 10 eyes, tumor recurrence after IAC in another 3 eyes and diffuse infiltrating retinoblastoma in 2 eyes. Six eyes (40%) were enucleated after a mean time interval of 4.8 (1-8) months. Cataract formation was the most common complication affecting 44.4% of the preserved eyes, yet 77.8% achieved a visual acuity of >20/200. Two of the 15 children treated developed metastatic disease during follow-up, resulting in a 13.3% metastasis rate. PBT is a useful treatment modality as a rescue therapy in retinoblastoma eyes with an eye-preserving rate of 60%. As patients are at lifetime risk of SPTs consistent monitoring is mandatory.

Identifiants

pubmed: 33924716
pii: cancers13081862
doi: 10.3390/cancers13081862
pmc: PMC8069965
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cancer. 2014 Jan 1;120(1):126-33
pubmed: 24122173
Tex Med. 2005 Jul;101(7):10
pubmed: 16152902
Klin Padiatr. 2010 May;222(3):127-33
pubmed: 20514614
Adv Radiat Oncol. 2017 Jan-Mar;2(1):44-52
pubmed: 28607957
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):583-93
pubmed: 15667981
Ophthalmology. 2014 Sep;121(9):1810-7
pubmed: 24819859
Clin Exp Ophthalmol. 2008 Jan-Feb;36(1):78-89
pubmed: 18290958
Annu Rev Med. 2014;65:171-84
pubmed: 24422571
Pediatr Blood Cancer. 2017 Jan;64(1):71-80
pubmed: 27567086
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):e151-5
pubmed: 23273995
J Natl Cancer Inst. 2009 Apr 15;101(8):581-91
pubmed: 19351917
Ophthalmology. 2006 Dec;113(12):2276-80
pubmed: 16996605
Front Radiat Ther Oncol. 1997;30:65-80
pubmed: 9205886
Yonsei Med J. 2015 Nov;56(6):1478-91
pubmed: 26446627
Curr Opin Ophthalmol. 2016 Sep;27(5):443-8
pubmed: 27213925
J Pediatr Hematol Oncol. 2018 Nov;40(8):569-573
pubmed: 29683953
Cancer Control. 2016 Apr;23(2):99-109
pubmed: 27218786
Acta Ophthalmol. 2018 Sep;96(6):631-640
pubmed: 29537141
Korean J Ophthalmol. 2017 Feb;31(1):52-57
pubmed: 28243024
Nat Rev Dis Primers. 2015 Aug 27;1:15021
pubmed: 27189421
Korean J Ophthalmol. 2011 Dec;25(6):387-93
pubmed: 22131775
Prog Retin Eye Res. 2019 Nov;73:100764
pubmed: 31173880
J Clin Oncol. 2000 Jan;18(1):12-7
pubmed: 10623688
Br J Radiol. 2020 Mar;93(1107):20190601
pubmed: 31529979
Br J Ophthalmol. 2009 Jul;93(7):891-4
pubmed: 19329423
J Clin Oncol. 2005 Apr 1;23(10):2272-9
pubmed: 15800318
J Natl Cancer Inst. 2008 Dec 17;100(24):1771-9
pubmed: 19066271
Ophthalmology. 2005 Sep;112(9):1620-4
pubmed: 16024083
J Clin Oncol. 2016 Sep 10;34(26):3183-8
pubmed: 27382102
Br J Ophthalmol. 2014 Mar;98(3):292-7
pubmed: 24187047
Br J Ophthalmol. 2014 Oct;98(10):1355-9
pubmed: 24795337
JAMA Ophthalmol. 2015 Nov;133(11):1341-7
pubmed: 26378747
Phys Med. 2017 Nov;43:15-24
pubmed: 29195558
J Neurointerv Surg. 2019 Dec;11(12):1266-1272
pubmed: 31103993
Am J Ophthalmol. 2002 May;133(5):657-64
pubmed: 11992863
Curr Opin Ophthalmol. 2012 May;23(3):202-9
pubmed: 22450222
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):863-9
pubmed: 25227498

Auteurs

Eva Biewald (E)

Department of Ophthalmology, University Hospital Essen, University Duisburg Essen, 45122 Essen, Germany.

Tobias Kiefer (T)

Department of Ophthalmology, University Hospital Essen, University Duisburg Essen, 45122 Essen, Germany.

Dirk Geismar (D)

Department of Particle Therapy, West German Proton Therapy Centre Essen (WPE), University Hospital Essen, German Cancer Consortium (DKTK), 45122 Essen, Germany.

Sabrina Schlüter (S)

Department of Ophthalmology, University Hospital Essen, University Duisburg Essen, 45122 Essen, Germany.

Anke Manthey (A)

Department of Ophthalmology, University Hospital Essen, University Duisburg Essen, 45122 Essen, Germany.

Henrike Westekemper (H)

Department of Ophthalmology, University Hospital Essen, University Duisburg Essen, 45122 Essen, Germany.

Jörg Wulff (J)

Department of Particle Therapy, West German Proton Therapy Centre Essen (WPE), University Hospital Essen, German Cancer Consortium (DKTK), 45122 Essen, Germany.

Beate Timmermann (B)

Department of Particle Therapy, West German Proton Therapy Centre Essen (WPE), University Hospital Essen, German Cancer Consortium (DKTK), 45122 Essen, Germany.

Petra Ketteler (P)

Department of Pediatric Hematology and Oncology, University Duisburg Essen, 45122 Essen, Germany.

Stefan Schönberger (S)

Department of Pediatric Hematology and Oncology, University Duisburg Essen, 45122 Essen, Germany.

Klaus A Metz (KA)

Institute of Pathology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.

Saskia Ting (S)

Institute of Pathology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.

Sophia Göricke (S)

Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.

Nikolaos E Bechrakis (NE)

Department of Ophthalmology, University Hospital Essen, University Duisburg Essen, 45122 Essen, Germany.

Norbert Bornfeld (N)

Department of Ophthalmology, University Hospital Essen, University Duisburg Essen, 45122 Essen, Germany.

Classifications MeSH